IPO | BioScience AI Baidu Hundreds of Diagrams Bioscience Plans Hong Kong Listing to Raise Hundreds of Millions of Dollars Founded by Baidu's Robin Li

SighingCashier

2026-03-16 06:45:07

Abstract generation in progress

According to Bloomberg, Baidu (09888) has confidentially submitted an IPO application for its life sciences AI company, BaiTu BioTech, to the Hong Kong Stock Exchange (00388), with a potential listing within this year, expected to raise hundreds of millions of dollars.

Sources familiar with the matter say BaiTu BioTech is in negotiations with China International Capital Corporation, Morgan Stanley, and UBS regarding the IPO. Details such as the fundraising scale and timing have not yet been finalized.

Data shows that BaiTu BioTech was co-founded in 2020 by Baidu co-founder Robin Li and Liu Wei, former CEO of Baidu Venture Capital. Both currently serve as Chairman and CEO, respectively. The company has developed an AI system capable of modeling biological mechanisms and assisting in predictions, which could improve the efficiency and success rate of drug development.

Strategic Partnership Agreement with Hong Kong Investment

Hong Kong Investment Management (HKIM) signed a strategic cooperation agreement with BaiTu BioTech in 2024, whereby HKIM will provide comprehensive resources and support for BaiTu BioTech’s future development in Hong Kong. BaiTu BioTech plans to establish its first international innovation center in Hong Kong.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.